Airway resistance and tissue elastance from input or transfer impedance in bronchoconstricted monkeys.

Ascaris suum (AS) challenge in nonhuman primates is used as an animal model of human asthma. The primary goal of this study was to determine whether the airways and respiratory tissues in monkeys that are bronchoconstricted by AS inhalation behave similarly to those in asthmatic humans. Airway resistance (Raw) and tissue elastance (Eti) were estimated from respiratory system input (Zin) or transfer (Ztr) impedance. Zin (0.4-20 Hz) and Ztr (2-128 Hz) were measured in anesthetized cynomolgus monkeys (n = 10) under baseline (BL) and post-AS challenge conditions. Our results indicate that AS challenge in monkeys produces 1) predominantly an increase in Raw and not tissue resistance, 2) airway wall shunting at higher AS doses, and 3) heterogeneous airway constriction resulting in a decrease of lung parenchyma effective compliance. We investigated whether the airway and tissue properties estimated from Zin and Ztr were similar and found that Raw estimated from Zin and Ztr were correlated [r(2) = 0.76], not significantly different at BL (13.6 +/- 1.4 and 13.1 +/- 0.9 cmH(2)O. l(-1). s(-1), respectively), but significantly different post-AS (20.5 +/- 4.5 cmH(2)O. l(-1). s(-1) and 18.5 +/- 5.2 cmH(2)O. l(-1). s(-1)). There was no correlation between Eti estimated from Zin and Ztr. The changes in lung mechanical properties in AS-bronchoconstricted monkeys are similar to those recently reported in human asthma, confirming that this is a reasonable model of human asthma.

Anti-LFA-1 alpha reduces the dose of cyclosporin A needed to produce immunosuppression in heterotopic cardiac transplanted rats.

BACKGROUND: Monoclonal antibodies (MAb) against cell adhesion molecules prolong the time to acute rejection of transplanted organs in animals. Postulated mechanisms of action include blockade of trafficking of host leukocytes into or recognizing of effector/target cells within the allograft. We examined whether an anti-ICAM-1 (1A29), anti-LFA-1 alpha (WT.1), or anti-CD-18 (WT.3) could reduce the immunosuppressive dose of cyclosporin A (CsA) when used in combination. METHODS: A rat heterotopic cardiac transplant model with ACI donors and Lewis recipients was used. MAb dose was 3 mg/kg, i.p. with treatment on Days -3 and -1 prior to transplant, followed by daily dosing for 10 days post-transplantation (Tx). Cyclosporin A doses were either 1.5 or 2.75 mg/kg, PO beginning the day of and for 10 days post-Tx. RESULTS: Untreated allografted rats demonstrated a mean rejection time (MRT) +/- SEM of 8.8 +/- 0.6 days. Cyclosporin A at 1.5 and 2.75 mg/kg showed mean rejection times of 8.5 +/- 0.3 (NS) and 20.5 +/- 1.9 (p < 0.05) days, respectively. Monotherapy with 1A29 or WT.3 did not prolong MRT, whereas WT.1 increased MRT to 21.7 +/- 4.3 days (p < 0.05). MAb combination therapy did not extend MRT greater than that demonstrated by WT.1 alone. However, MAb and CsA combination therapy significantly increased MRT with WT.1 and CsA resulting in the greatest extension. WT.1 combination with CsA at 1.5 mg/kg and 2.75 mg/kg increased MRT to > 46.8 +/- 6.3 and > 44.2 +/- 9.4 days, respectively. CONCLUSIONS: Anti-LFA-1 alpha and CsA combination therapy significantly extends the time to rejection of transplanted rat hearts. We conclude that combining an anti-LFA-1 alpha and CsA may be beneficial in prolonging allograft rejection times and in reducing the amount of CsA necessary for immune suppression, thereby minimizing its toxic effects.

Cyclosporine dosage can be reduced when used in combination with an anti-intercellular adhesion molecule-1 monoclonal antibody in rats undergoing heterotopic heart transplantation.

BACKGROUND: Intercellular adhesion molecule-1 (ICAM-1) is believed to play a role in acute rejection of allografted tissues. This molecule is involved in the interaction of T cells with antigen-presenting cells expressed on the vascular endothelium of transplanted organs and is involved in the adhesion of inflammatory cells to this endothelium and their subsequent migration into the underlying tissues. METHODS: Rat abdominal heterotopic heart transplantation was used to study the role of ICAM-1 in the rejection process. American Cancer Institute rats were used as donors; Lewis rats were used as recipients. Graft survival was monitored daily via donor heart palpation. Nine groups (n = 6/group) were studied: untreated controls; olive oil; cyclosporine at 1.5, 2.75, and 5.0 mg/kg, respectively; R3.1, a control monoclonal antibody; 1A29, a rat anti-ICAM-1 monoclonal antibody, 3 mg/kg administered intraperitoneally; a combination of 1A29 (3 mg/kg) and cyclosporine (1.5 mg/kg); and a combination of 1A29 (3 mg/kg) and cyclosporine (2.75 mg/kg). RESULTS: Mean rejection time was 8.8 +/- 0.6 days for the untreated allografted controls and 9.7 +/- 1.1 days for the olive oil controls. Cyclosporine (1.5, 2.75, and 5.0 mg/kg) showed mean rejection times of 8.5 +/- 0.3, 20.5 +/- 1.9, and 28.8 +/- 3.6 days, respectively. The 1A29 treatment showed a mean rejection time of 9.3 +/- 0.7 days. Combination therapy of 1A29 and cyclosporine at 1.5 or 2.75 mg/kg demonstrated mean rejection times of 17.7 +/- 3.3 and 29.2 +/- 6.7 days, respectively. Thus 1A29 alone does not prolong cardiac allograft survival; however, combination therapy with either a subthreshold or a moderate dose of cyclosporine significantly extends the time to rejection of heterotopically transplanted rat hearts. CONCLUSIONS: Although monotherapy with an ICAM-1 antagonist alone may not be beneficial in preventing acute rejection episodes after organ transplantation, combination therapy of an anti-ICAM-1 monoclonal antibody may allow for a reduction in the dose of cyclosporine necessary for immune suppression. Such a reduction could lead to a lowering of the incidence of nephrotoxicity and other side effects associated with long-term cyclosporine administration.

Determination of airway and tissue resistances after antigen and methacholine in nonhuman primates.

Antigen challenge of Ascaris suum-sensitive animals has been used as a model of asthma in humans. However, no reports have separated total respiratory resistance into airway (Raw) and tissue (Rti) components. We compared input impedance (Zin) and transfer impedance (Ztr) to determine Raw and Rti in anesthetized cynomolgus monkeys under control and bronchoconstricted conditions. Zin data between 1 and 64 Hz are frequency dependent during baseline conditions, and this frequency dependence shifts in response to A. suum or methacholine. Thus it cannot be modeled with the DuBois model, and estimates of Raw and Rti cannot be determined. With Ztr, baseline data were much less variable than Zin in all monkeys. After bronchial challenge with A. suum or methacholine, the absolute amplitude of the resistive component of Ztr increased and its zero crossing shifted to higher frequencies. These data can estimate Raw and Rti with the six-element DuBois model. Therefore, in monkeys, Ztr has advantages over other measures of lung function, since it provides a methodology to separate estimates of Raw and Rti. In conclusion, Ztr shows spectral features similar to those reported in healthy and asthmatic humans.

Captopril-induced hypotension is inhibited by the bradykinin blocker HOE-140 in Na(+)-depleted marmosets.

Inhibition of angiotensin-converting enzyme (ACE) inhibits formation of angiotensin II and, by inhibition of kinin metabolism, may also increase vascular bradykinin. The present experiments were done in sodium-depleted, conscious, unrestrained marmosets (n = 5-11) to examine the contribution of bradykinin to ACE inhibitor-induced hypotension. Aortic blood pressure and heart rate (HR) were monitored via telemetry. After sodium depletion (low-sodium diet and furosemide), captopril (1 mg/kg po) caused a significant (P < 0.05) decrease in mean arterial blood pressure (MABP) (-34 +/- 3 mmHg, maximally, from 79 +/- 2 mmHg) but no change in HR compared with vehicle treatment. The bradykinin receptor antagonist HOE-140 (1 mg/kg sc) significantly inhibited the hypotensive response to captopril and caused marked tachycardia (+133 +/- 14 beats/min from 214 +/- 8 beats/min). HOE-140 (1 mg/kg sc) followed by vehicle administration had no effect on MABP but increased HR similarly. The hypotensive response to captopril was inhibited by HOE-140 regardless of the order of administration or the route of captopril administration (by mouth vs. subcutaneously). The hypotensive response to a renin inhibitor, A-72517 (3 mg/kg sc), was not inhibited by prior HOE-140 administration despite a similar HOE-140-induced tachycardia. These data suggest that the hypotensive effect of captopril in sodium-depleted, conscious marmosets is dependent on functional bradykinin B2 receptors. Also, blockade of B2 receptors uncovers marked tachycardia in this model, suggesting a tonic effect of bradykinin on control of HR in marmosets.

Differential effects of L-NAME on blood pressure and heart rate responses to acetylcholine and bradykinin in cynomolgus primates.

NG-nitro-L-arginine methyl ester (L-NAME) has been reported to have variable effects on the vasodilator response to acetylcholine (ACh) and bradykinin (BK) in vivo. Whether administration of L-NAME affects mean arterial pressure (MAP) or heart rate (HR) responses to ACh or BK was examined in conscious cynomolgus primates. ACh (0.1-10 micrograms/kg i.v.) lowered MAP by 6% to 37%, responses which were inhibited (25-62%) in the presence of L-NAME (1-100 mg/kg i.v.). Although L-NAME increased MAP similarly at doses of 10 and 100 mg/kg, only the 100-mg/kg dose inhibited the hypotensive responses induced by the higher doses of ACh. By comparison, nitroprusside (5 micrograms/kg i.v.)-induced hypotensive responses were not inhibited by L-NAME. Phenylephrine (20 micrograms kg-1 min-1 i.v.) increased MAP and lowered HR to levels statistically similar to that of L-NAME but did not alter ACh-induced hypotensive responses. ACh dose-dependently decreased HR, both in the absence and presence of L-NAME or phenylephrine. In pentobarbital-anesthetized monkeys, ACh-induced hypotensive responses were inhibited by 75% to 94% in the presence of L-NAME; BK (0.3-1 microgram/kg i.v.) responses were only modestly affected (< or = 50%). Therefore, in conscious primates, L-NAME affects the basal release of nitric oxide (NO) at lower doses than those required to inhibit its release stimulated by ACh. Also, L-NAME does not appear to act as a cholinergic antagonist or affect the functional mechanisms that control baroreflex responses.(ABSTRACT TRUNCATED AT 250 WORDS)

Sodium depletion in conscious cynomolgus monkeys attenuates baroreflex sensitivity independently of prostaglandins.

We tested the hypothesis that baroreflex attenuation during sodium depletion is due to increased prostaglandin (PG) levels. We studied baroreflex sensitivity before and after PG synthesis inhibition in conscious cynomolgus monkeys. Arterial pressure and pulse interval (PI) were measured during intravenous infusions of phenylephrine (1-20 micrograms.kg-1.min-1, n = 6) and nitroprusside (1-10 micrograms.kg-1.min-1, n = 7). Infusions were repeated 30 min after indomethacin (Indo, 6 mg/kg iv). The slope (in ms/mmHg) of the mean arterial blood pressure-PI plot was used as an index of baroreflex sensitivity. Plasma renin activity (PRA) was elevated (47.9 +/- 9.7 vs. 8.8 +/- 3.3 ng angiotensin I.ml-1.h-1) after sodium depletion (P < 0.05). Baroreflex sensitivity to hypotension and hypertension was significantly (P < 0.05) attenuated by sodium depletion (3.69 +/- 0.9 vs. 0.9 +/- 0.1 ms/mmHg and 7.38 +/- 0.6 vs. 5.04 +/- 0.9 ms/mmHg, respectively). Indo decreased PRA to 28.6 +/- 5.7 ng angiotensin I.ml-1.h-1 (P < 0.05) in sodium-depleted monkeys and decreased heart rate -21 +/- 3.7 from a baseline of 166 +/- 9.40 beats/min in normal monkeys and -22 +/- 2.9 from a baseline of 191 +/- 7.9 beats/min in low-sodium monkeys (P < 0.05). Indo did not significantly change baroreflex sensitivity in either group. Thus the baroreflex was attenuated in conscious nonhuman primates during sodium depletion; acute PG synthesis blockade did not improve baroreflex sensitivity. Indo decreased heart rate without changing arterial pressure; suggesting that PGs caused a downward resetting of the pressure-heart rate relationship.

Effects of losartan (DuP753) and enalaprilat on the mean arterial pressure response to phenylephrine.

BACKGROUND: We have found that low-dose infusion of angiotensin II (Ang II) selectively potentiates the mean arterial pressure (MAP) response to phenylephrine in pentobarbital-anesthetized rabbits. OBJECTIVE: To examine whether endogenous Ang II levels in normotensive rabbits maintained on a normal-salt diet exert a potentiating effect on the MAP response to phenylephrine. METHODS: We compared the effects of enalaprilat (0.3 mg/kg per min for 5 min bolus, 1 mg/kg per h infusion), losartan (DuP753; 4 mg/kg bolus, 2 mg/kg per h infusion) and vehicle administration on the MAP response to infusions of phenylephrine that were increased incrementally (2.5, 5 and 10 micrograms/kg per min). RESULTS: Enalaprilat decreased MAP significantly, whereas no maintained change was observed with losartan or vehicle. Phenylephrine infusions elevated MAP significantly and dose-dependently in all of the rabbits studied, but this effect was attenuated significantly in the rabbits given losartan compared with in those given vehicle or enalaprilat. The heart rate responses were not significantly different among the three groups. CONCLUSION: We conclude that inhibition of the renin-angiotensin system at two distinct sites results in different MAP responses to phenylephrine infusion.

Heart rate response to hemorrhage-induced 0.05-Hz oscillations in arterial pressure in conscious dogs.

We have previously reported that oscillations at 0.05 Hz can be generated by a simple computer model incorporating a negative-feedback reflex mechanism and an effector mechanism with a time delay. Computer simulations by inhibiting the vagal effector mechanism and activating the adrenergic effector mechanism elicited low-frequency oscillations at a frequency of 0.05 Hz in heart rate. We have observed that the cardiovascular system of the conscious dog, when stressed by the loss of blood, generates oscillations in arterial pressure and heart rate at a frequency of 0.05 Hz. We investigated in six conscious dogs the role of the sympathetic and parasympathetic nervous systems in generating these heart rate oscillations. During baseline conditions, the predominant peak in the arterial pressure and heart rate power spectra was located at the respiratory frequency, while the low-frequency oscillations were small. After a 30-ml/kg hemorrhage or after an 8-, 15-, or 30-ml/kg hemorrhage with glycopyrrolate, a muscarinic-blocking agent, low-frequency oscillations at a frequency of 0.05 Hz predominated, while the respiratory frequency oscillations were negligible. Since respiratory frequency oscillations have been reported to reflect vagal activity, and since the low-frequency oscillations were present after vagal blockade, these hemorrhage-induced low-frequency oscillations in heart rate may be primarily mediated by the cardiac sympathetic nerves. Also cross-correlation analysis between arterial pressure and heart rate showed that a change in arterial pressure caused an opposite change in heart rate with a delay of 2-5 s. We conclude that hemorrhage-induced oscillations in heart rate at 0.05 Hz represent the arterial baroreceptor-beta-sympathetic reflex response to underlying arterial pressure oscillations.

Pentobarbital anesthesia alters renal actions of alpha-hANP in dogs.

The magnitude of the natriuretic response to an infusion of alpha-human atrial natriuretic peptide (alpha-hANP) has varied considerably in different studies. The greatest renal responses to alpha-hANP infusion have been observed in barbiturate-anesthetized dogs. We therefore examined the renal, hormonal, and cardiovascular responses to alpha-hANP infusion in eight female dogs, once awake and again anesthetized with pentobarbital sodium (25 mg/kg body wt). After a 20-min control period, alpha-hANP was infused at a rate of 25 ng.kg-1.min-1 for 60 min. In dogs when awake, infusion of alpha-hANP produced a significant increase in sodium excretion from a control value of 39 +/- 7 to 73 +/- 13 and 89 +/- 15 mu eq/min after 40 and 60 min. In dogs when anesthetized, infusion of alpha-hANP produced an increase in sodium excretion from 21 +/- 3 to 105 +/- 12 and 143 +/- 21 mu eq/min after 40 and 60 min. The increase in sodium excretion was significantly greater in dogs when anesthetized than when awake. We also investigated the role of the renal sympathetic nerves on these responses in six dogs after chronic bilateral renal denervation. In dogs with denervated kidneys when awake, infusion of alpha-hANP did not change sodium excretion significantly. In dogs with denervated kidneys when anesthetized, infusion of alpha-hANP significantly increased sodium excretion; however, the increase was significantly attenuated when compared with anesthetized dogs with intact kidneys. We conclude that the natriuretic response to an infusion of alpha-hANP is enhanced in dogs when anesthetized. Also, the natriuretic response was attenuated by renal denervation in dogs when anesthetized.

Low-frequency oscillations in arterial pressure and heart rate: a simple computer model.

We have previously reported that low-frequency oscillations in arterial blood pressure (ABP) and heart rate (HR) occur when conscious dogs experience severe blood loss. These low-frequency oscillations are generated by enhancement of the sympathetic nervous system and inhibition of the parasympathetic nervous system. We have developed a simple computer model to elucidate those properties critical to the generation of these oscillations. Our model incorporates several important features: 1) arterial baroreceptor feedback loops, which relate ABP to targeted HR and total peripheral resistance (TPR) values; 2) two effector outputs, HR and TPR, which are controlled by the outputs of vagal, beta-adrenergic, and alpha-adrenergic effector mechanisms; 3) a fixed beat-to-beat stroke volume; and 4) a wind-kessel model, which represents the peripheral circulation. Each effector mechanism is modeled as a low-pass filter in series with a delay. The vagal effector mechanism slows the HR after a 100-ms delay and reaches maximal HR at that time. The beta-adrenergic effector mechanism speeds HR after a 2.5-s delay and then increases to maximal HR 7.5 s later. The alpha-adrenergic effector mechanism begins vasoconstriction after a 5-s delay and then reaches maximal contraction 15 s later. Computer simulations of inhibition of the vagal effector mechanism and activation of the adrenergic effector mechanisms elicit low-frequency oscillations in ABP and HR. These oscillations are similar to those observed experimentally in the dog during hemorrhage. We conclude that the slow temporal response of the alpha-adrenergic effector mechanism controlling TPR is the critical element in predicting the observed low-frequency oscillations in ABP and HR.

Cardiovascular, renal, and endocrine responses to intravenous endothelin in conscious dogs.

Endothelin is a recently discovered vasoconstrictor peptide that is synthesized in certain vascular endothelial cells. We have identified the cardiovascular, renal, and hormonal responses that can be elicited in conscious dogs by intravenous administration of endothelin at rates of 10 and 30 ng.kg-1.min-1 for 60 min (0.24 and 0.72 nmol.kg-1/1-h infusion). Each dose of endothelin increased total peripheral resistance, arterial pressure, and left atrial pressure and decreased heart rate and cardiac output. Hematocrit increased by 4.8% (NS) and 22.9% (P less than 0.01) in response to the lower and higher infusion rates, respectively. Urinary sodium excretion, urine osmolality, and osmolar clearance decreased and free water clearance increased. The lower dose of endothelin decreased plasma norepinephrine and increased plasma atriopeptin. The higher dose increased plasma levels of vasopressin, renin, aldosterone, norepinephrine, epinephrine, and atriopeptin. The higher infusion rate of the peptide caused one or more brief vomiting episodes in four of five dogs. Although it is not yet known whether endothelin is a circulating hormone, it is clear that this peptide is capable of causing profound cardiovascular, renal, and endocrine alterations in conscious dogs. The possible relevance of these observations to physiological processes and to pathological conditions such as hypertension remains to be established.

Hemodynamic regulation: investigation by spectral analysis.

We investigated the hypothesis that beat-to-beat variability in hemodynamic parameters reflects the dynamic interplay between ongoing perturbations to circulatory function and the compensatory response of short-term cardiovascular control systems. Spontaneous fluctuations in heart rate (HR), arterial blood pressure, and respiration were analyzed by spectral analysis in the 0.02- to 1-Hz frequency range. A simple closed-loop model of short-term cardiovascular control was proposed and evaluated in a series of experiments: pharmacological blockades of the parasympathetic, alpha-sympathetic, beta-sympathetic, and renin-angiotensin systems were used to open the principal control loops in order to examine changes in the spectral pattern of the fluctuations. Atrial pacing was used to examine blood pressure variability in the absence of HR variability. We found that respiratory frequency fluctuations in HR are parasympathetically mediated and that blood pressure fluctuations at this frequency result almost entirely from the direct effect of centrally mediated HR fluctuations. The sympathetic nervous system appears to be too sluggish to mediate respiratory frequency variations. Low-frequency (0.02-0.09 Hz) fluctuations in HR are jointly mediated by the parasympathetic and beta-sympathetic systems and appear to compensate for blood pressure fluctuations at this frequency. Low-frequency blood pressure fluctuations are probably due to variability in vasomotor activity which is normally damped by renin-angiotensin system activity. Blockade of the alpha-adrenergic system, however, does not significantly alter low-frequency blood pressure fluctuations.